Endokrynologia Polska最新文献

{"title":"Previous, simultaneous, or subsequent occurrence of malignant tumours in patients with primary hyperparathyroidism: a closer look at the single-tertiary-centre cases.","authors":"Havva Sezer,&nbsp;Hande Bulut Canbaz,&nbsp;Serdar Tezalman,&nbsp;Tarık Terzioğlu,&nbsp;Eda Nur Çilingiroğlu,&nbsp;Bülent Çolakoğlu,&nbsp;Dilek Yazıcı,&nbsp;Oğuzhan Deyneli,&nbsp;Mehmet Onur Demirkol,&nbsp;Adnan Batman,&nbsp;Seçil Özışık,&nbsp;Yersu Yapran,&nbsp;Faruk Alagöl","doi":"10.5603/EP.a2023.0055","DOIUrl":"https://doi.org/10.5603/EP.a2023.0055","url":null,"abstract":"<p><strong>Introduction: </strong>Our aims were to explore the relationship between primary hyperparathyroidism (pHPT) and malignant tumour development, to determine the frequency and the time of occurrence of malignant tumours in patients with pHPT, and to evaluate the characteristics of pHPT in these patients.</p><p><strong>Material and methods: </strong>This retrospective cohort study included consecutive individuals who were diagnosed with pHPT aged 18 years or older in a university hospital during a 7-year period. A total of 198 patients with pHPT were reviewed retrospectively. Demographic, clinical, biochemical, radiologic findings, and histopathological diagnosis were collected from the electronic medical records of the hospital system.</p><p><strong>Results: </strong>The mean age of the study population was 58 ± 13 years and was predominantly female (female/male: 162/36). There were 42 (21.2%) patients with malignant tumours. Five (12%) out of 42 patients had metachronous double malignancies. The most common 2 concurrent malignancies were breast (36.1%) and thyroid (17.0%). Sixty-eight per cent of the malignant tumours occurred before the diagnosis of pHPT. A higher percentage (87.5%) of simultaneous tumours was seen in the thyroid gland. No statistically significant differences were observed between patients with and without malignant tumours in terms of demographic, clinical, biochemical, radiological, and histopathological features. The median follow-up duration was 24 months after parathyroid surgery.</p><p><strong>Conclusion: </strong>The results of this study revealed that pHPT was associated with various tumour types. The frequency of malignant tumours was 21.2%. Breast and thyroid cancers were the most common 2 cancers coexisting with pHPT. A large percentage of malignant tumours occurred before the diagnosis of pHPT. A higher percentage of simultaneous tumours was seen in the thyroid gland. pHPT patients with and without malignant tumours seemed to have similar characteristics.</p>","PeriodicalId":11551,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9982031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lethargic patient with hepatocirrhosis - more than meets the eye.","authors":"Mateusz Maligłówka,&nbsp;Aleksandra Sojka,&nbsp;Anna Bartecka,&nbsp;Łukasz Bułdak,&nbsp;Bogusław Okopien","doi":"10.5603/EP.a2023.0050","DOIUrl":"https://doi.org/10.5603/EP.a2023.0050","url":null,"abstract":"<p><p>Not required for Clinical Vignette.</p>","PeriodicalId":11551,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9982034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Difficulties in achieving euthyroid status in a patient with differentiated thyroid cancer after sleeve gastrectomy.","authors":"Adam Daniel Durma,&nbsp;Marek Saracyn,&nbsp;Anna Celina Durma,&nbsp;Grzegorz Kamiński","doi":"10.5603/EP.a2023.0047","DOIUrl":"https://doi.org/10.5603/EP.a2023.0047","url":null,"abstract":"<p><p>Not required for Clinical Vignette.</p>","PeriodicalId":11551,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9982035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between TSH suppression therapy and type 2 deiodinase gene polymorphism in differentiated thyroid carcinoma.","authors":"Xiaoke Zheng,&nbsp;Lichang Zhong,&nbsp;Tianjiao Zhou,&nbsp;Feng Zhao,&nbsp;Bin Chen","doi":"10.5603/EP.a2023.0043","DOIUrl":"https://doi.org/10.5603/EP.a2023.0043","url":null,"abstract":"<p><strong>Introduction: </strong>Oral levothyroxine (L-T4) suppression of thyroid-stimulating hormone (TSH) levels is the most commonly used clinical approach to manage and treat patients after thyroid cancer surgery. This study aimed to investigate the association between TSH suppression therapy and type 2 deiodinase gene (DIO2) polymorphism in differentiated thyroid carcinoma (DTC).</p><p><strong>Material and methods: </strong>A total of 240 patients with DTC who received total thyroidectomy (TT; 120) and hemithyroidectomy (HT; 120) were enrolled in this study. The serum TSH, free triiodothyronine (FT3), and free thyroxine (FT4) levels were detected using an automatic serum immune analyser and electrochemiluminescence immunoassay. Based on the results of DIO2 gene detection, 3 genotypes of Thr92Ala were detected.</p><p><strong>Results: </strong>The serum TSH levels were inhibited after oral L-T4 treatment, but the proportion of patients who reached the TSH suppression standard in the hemithyroidectomy group was higher than in the total thyroidectomy group. After TSH suppression treatment, serum FT4 levels were increased in both total thyroidectomy and hemithyroidectomy. The difference in serum TSH, FT3, and FT4 levels was associated with different genotypes, and patients with high cytosine cytosine (CC) genotypes may have difficulty meeting the TSH suppression criteria.</p><p><strong>Conclusions: </strong>Patients who underwent total thyroidectomy exhibited higher postoperative serum FT4 levels than patients in the hemithyroidectomy group after TSH suppression therapy. The Thr92Ala polymorphism of type 2 deiodinase (D2) was associated with TSH suppression therapy.</p>","PeriodicalId":11551,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9823345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in clinical characteristics, treatment, and outcomes of sporadic and MEN-1-related insulinomas.","authors":"Marta Opalińska,&nbsp;Aleksandra Gilis-Januszewska,&nbsp;Karolina Morawiec-Sławek,&nbsp;Anna Kurzyńska,&nbsp;Anna Sowa-Staszczak,&nbsp;Anna Bogusławska,&nbsp;Ewelina Rzepka,&nbsp;Alicja Hubalewska-Dydejczyk","doi":"10.5603/EP.a2023.0049","DOIUrl":"https://doi.org/10.5603/EP.a2023.0049","url":null,"abstract":"<p><strong>Introduction: </strong>Although in most cases insulinomas are small, benign, sporadic tumours, they can also be associated with hereditary syndromes, most commonly multiple endocrine neoplasia type 1 (MEN-1). Such a diagnosis significantly affects patient management. The objective was to elucidate the clinical differences between sporadic and MEN-1-linked insulinoma.</p><p><strong>Material and methods: </strong>Comparison of clinical and histopathological characteristics, types of surgery, and outcomes of patients with sporadic and MEN-1-related insulinoma diagnosed between 2015 and 2022.</p><p><strong>Results: </strong>There were 17 cases of insulinomas that underwent MEN-1 genetic testing (10 women and 7 men). In 7 cases, the mutation in the menin gene was confirmed. The median age at the time of diagnosis of sporadic insulinoma related to MEN-1 was 69 years (range 29-87) and 31.5 years (16-47), respectively. Primary hyperparathyroidism (PHP) was found in 6 of 7 patients with MEN-1-related insulinoma, while in none of the patients without MEN-1 mutations. Multifocal pancreatic NETs were found in 3 patients with MEN-1 syndrome, while in all sporadic cases there was a single pancreatic tumour. Two patients with insulinoma related to MEN-1 had a positive familial history of MEN-1-related diseases, while none with sporadic form. Dissemination at diagnosis was found in 4 cases, including 3 patients with insulinoma related to MEN-1-related insulinoma. Patients with sporadic and MEN-1-related insulinoma did not differ in tumour size, Ki-67 proliferation index, and outcome.</p><p><strong>Conclusions: </strong>Of all the features evaluated, only the multifocal nature of pancreatic neuroendocrine tumour (PanNET) lesions and a positive family history differentiated between patients with sporadic and MEN-1-related insulinomas. An age of insulinoma diagnosis of less than 30 years may be a strong indicator of an increased risk of MEN-1 syndrome.</p>","PeriodicalId":11551,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9823347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic and therapeutic difficulties in a patient with corticotropic pituitary macroadenoma.","authors":"Grzegorz Erbert,&nbsp;Elżbieta Łomna-Bogdanov,&nbsp;Marek Bolanowski","doi":"10.5603/EP.a2023.0044","DOIUrl":"https://doi.org/10.5603/EP.a2023.0044","url":null,"abstract":"<p><p>Not required for Clinical Vignette.</p>","PeriodicalId":11551,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9823350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The influence of SGLT2 inhibitors on oxidative stress in heart failure and chronic kidney disease in patients with type 2 diabetes.","authors":"Diana Nabrdalik-Leśniak,&nbsp;Katarzyna Nabrdalik,&nbsp;Krzysztof Irlik,&nbsp;Oliwia Janota,&nbsp;Hanna Kwiendacz,&nbsp;Paulina Szromek-Białek,&nbsp;Mirosław Maziarz,&nbsp;Tomasz Stompór,&nbsp;Janusz Gumprecht,&nbsp;Gregory Y H Lip","doi":"10.5603/EP.a2023.0039","DOIUrl":"https://doi.org/10.5603/EP.a2023.0039","url":null,"abstract":"<p><p>There is increasing interest in sodium-glucose cotransporter 2 inhibitors (SGLT2i) as not only a new oral glucose-lowering drug class but also one with cardio- and nephroprotective potential. Understanding the underlying mechanisms is therefore of great interest, and postulated benefits have included increased natriuresis, lower blood pressure, increased haematocrit, enhanced cardiac fatty acid utilization, reduced low-grade inflammation, and decreased oxidative stress. In particular, redox homeostasis seems to be crucial in the pathogenesis of heart and kidney disease in diabetes, and there is accumulating evidence that SGLT2i have beneficial effects in this perspective. In this review, we aimed to summarize the potential mechanisms of the influence of SGLT2i on oxidative stress parameters in animal and human studies, with a special focus on heart failure and chronic kidney disease in diabetes mellitus.</p>","PeriodicalId":11551,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9823346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperandrogenism-related metabolic changes in drug-naïve transmen compared to cisgender women: a case-controlled study.","authors":"P. Erel, O. Elbasan, Neşe Yorguner, E. Imre, Özlem Üstay","doi":"10.1530/endoabs.90.p177","DOIUrl":"https://doi.org/10.1530/endoabs.90.p177","url":null,"abstract":"INTRODUCTION\u0000The aetiology of gender dysphoria is still unclear. Although prior studies have shown that trans men have higher androgen levels than cisgender women, they all concluded unselected populations. Our reason for performing this study is to evaluate trans men's hormone profile and metabolic status to compare with cisgender women in a more selected population. This is the first case-controlled study to compare anthropometric, metabolic, and endocrinological parameters of drug-naïve trans men with those of cisgender women.\u0000\u0000\u0000MATERIAL AND METHODS\u0000We designed this study as a single-centre observational cohort study. We included 70 drug naïve trans men, and the control group comprised 34 healthy cisgender women. We measured and compared hormone profiles and metabolic parameters in the 2 groups.\u0000\u0000\u0000RESULTS\u0000Of the 70 trans men individuals, 16 (22.85%) met the Rotterdam criteria and were diagnosed with polycystic ovary syndrome (PCOS); 4 individuals in the control group met the criteria (11.7%). Although we matched body mass index in the groups, total testosterone, free androgen index, androstenedione, 17 hydroxyprogesterone, muscle strength, triglyceride, and homeostatic model assessment of insulin resistance levels were significantly higher in the trans men than in the cisgender women (p < 0.05). Even after were excluded PCOS patients, hyperandrogenaemia was apparent in the trans men.\u0000\u0000\u0000CONCLUSION\u0000Our study showed that trans men have clearly higher androgen levels, which may have been the reason for metabolic changes compared to cisgender women. However, the main reason for hyperandrogenism in drug-naïve trans men is still not known, and more comprehensive studies are needed.","PeriodicalId":11551,"journal":{"name":"Endokrynologia Polska","volume":"1 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47734807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute adrenal insufficiency secondary to bilateral adrenal haemorrhage.","authors":"Maciej Migacz,&nbsp;Klaudyna Borucka,&nbsp;Dariusz Kajdaniuk,&nbsp;Bogdan Marek","doi":"10.5603/EP.a2023.0027","DOIUrl":"https://doi.org/10.5603/EP.a2023.0027","url":null,"abstract":"<p><p>Not required for Clinical Vignette.</p>","PeriodicalId":11551,"journal":{"name":"Endokrynologia Polska","volume":"74 2","pages":"213-214"},"PeriodicalIF":2.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9431783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hazard ratios of second primary malignancy after radioiodine for differentiated thyroid carcinoma: a large-cohort retrospective study.","authors":"Weiming Wu,&nbsp;Shujie Li,&nbsp;Ke Xu,&nbsp;Zhaowei Meng","doi":"10.5603/EP.a2023.0028","DOIUrl":"https://doi.org/10.5603/EP.a2023.0028","url":null,"abstract":"<p><strong>Introduction: </strong>The objective of this study is to evaluate the benefits of radioactive iodine (RAI) treatment and the risk of second primary malignancy (SPM) in RAI-treated patients.</p><p><strong>Material and methods: </strong>The cohort for this analysis consisted of individuals diagnosed with a first primary differentiated thyroid carcinoma (DTC), reported by the Surveillance, Epidemiology, and End Results (SEER) database in 1988-2016. Overall survival (OS) difference was estimated by Kaplan-Meier curves and log-rank test, and hazard ratios (HR) were obtained by Cox proportional-hazards model to evaluate the association between RAI and SPM.</p><p><strong>Results: </strong>Among 130,902 patients, 61,210 received RAI and 69,692 did not, and a total of 8604 patients developed SPM. We found that OS was significantly higher in patients who received RAI than in those who did not (p < 0.001). DTC survivors treated with RAI had increased risk of SPM in females (p = 0.043), particularly for SPM occurring in the ovary (p = 0.039) and leukaemia (p < 0.0001). The risk of developing SPM was higher in the RAI group than in the non-RAI group and the general population, and the incidence increased with age.</p><p><strong>Conclusions: </strong>Increased risk of SPM occurs in female DTC survivors treated with RAI, which become more obvious with increasing age. Our research findings were beneficial to the formulation of RAI treatment strategies and the prediction of SPM for patients with thyroid cancer of different genders and different ages.</p>","PeriodicalId":11551,"journal":{"name":"Endokrynologia Polska","volume":"74 3","pages":"260-270"},"PeriodicalIF":2.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10204796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}